Investegate |Sensyne Health PLC Announcements | Sensyne Health PLC: Sensyne and OMNY Health Sign Teaming Agreement
Investegate announcements from Sensyne Health PLC, Sensyne and OMNY Health Sign Teaming Agreement
Stay updated with breaking news from Drayson Phd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Sensyne Health PLC, Sensyne and OMNY Health Sign Teaming Agreement
Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate
Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company's primary listing on the AIM market of the London ...
Drayson Technologies Develops Next Generation Biometric Smart Cards Powered by Freevolt Energy Harvesting Innovate UK funded project enabled Drayson Technologies to develop "Plug-n-Play" reference designs of its Freevolt radio frequency energy harvesting technology, delivering 3x more power for biometric smart card applications in secure access, cryptocurrency, healthcare and finance Drayson Technologies today announces the completion its Smart Grant project, funded by Innovate UK, the UK's innovation agency. During the 6-month project, the business received over £112,000 of funding in order...
Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ("FY 2021"), and an outlook statement. UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by...